Output Explorer

1. Q1 2026 total revenue was $526 million, representing 1% organic growth but a 12% reported decline due to the deconsolidation of the IV Solutions joint venture.
2. Adjusted EBITDA for the quarter was $99 million, matching the prior year level, while adjusted diluted EPS increased 15% year-over-year to $1.97.
3. Adjusted gross margin expanded to 41%, driven by favorable product mix as higher-margin consumables and infusion systems grew faster than the Vital Care segment.
4. The company recognized $10 million in tariff expenses in Q1, which accounted for approximately 2% of adjusted revenue.
5. Free cash flow for the quarter was $28 million, with management maintaining a full-year guidance target of approximately $150 million.
6. Infusion Systems achieved a record revenue quarter with 8% reported growth and 6% organic growth, with management now expecting growth to be balanced throughout the year rather than back-half weighted.
7. FDA approval for new Medfusion and CADD infusion pump hardware platforms has been delayed as the agency requires additional testing data involving larger sample sizes.
8. Management estimates that a $10 increase in the price of a barrel of oil results in $3 million of annualized incremental logistics expense, projecting roughly $10 million in additional costs for 2026.
9. Vital Care revenue decreased 14% organically and 59% reported, with management citing the exit of non-core SKUs, including a Japanese surgical commodities line that has declined over 50% cumulatively.
10. Despite emerging macroeconomic risks regarding oil prices and trade policies, management reaffirmed its full-year 2026 guidance for revenue, EBITDA, and EPS.

{
  "facts": [
    "1. ICU Medical, Inc. (NASDAQ:ICUM) reported revenue of $526 million for the first quarter of 2026, representing a 1% organic growth and a 12% reported decline due to the mid-2025 creation of the Otsuka ICU Medical joint venture and deconsolidation of IV Solutions from the income statement. Gross margins increased sequentially and were above 41% driven by favorable product mix with higher-margin core business units. Adjusted EBITDA was $99 million and adjusted EPS was $1.97. Free cash flow was strong, and there was no real change in net leverage. The broader demand and utilization environment in Q1 was previewed on the last call. The sharp flu spike in late 2025 did soften January, but volumes returned to expected levels from February onwards and feels fine through today.",
    "2. ICU Medical's consumables business grew 5% in Q1 reported and 2% organic. As previewed on the February call, Q1 revenues were down sequentially and in line with our expectations as we knew the changing environment from December to January. For Q2, we would expect growth rates to return to our historical levels. Our IV Systems business grew 8% reported and 6% organic, and it was again a record quarter in pumps. Dedicated sets generally follow the same trend as consumables and capital sales were strong through the quarter. For Q2 and the near term, we would expect organic growth to continue at this rate or above while absorbing the previously mentioned OEM wind down. Just wrapping up the businesses, Vital Care decreased 14% on an organic basis and decreased 59% reported due to the deconsolidation of IV Solutions. We've mostly wrapped up the work described on the last call of discontinuing certain SKUs as we had more contractual or operational flexibility with the largest impact of this felt now in Q1. I'll come back with an example of this shortly. We believe we should see sequential stability to improvement organically here and continue to believe the right revenue assumption for the near term is flat to slightly down in the face of our decisions to improve profitability. I wanted to close the business unit commentary with some updates on the different product development initiatives within the company. As we've mentioned more recently, we've been increasing the volume of new 510(k) submissions for our consumables offerings where the innovation is more incremental and intended to create new adjacent niches. Last year, we received a new 510(k) for our core microclve and Neutron needle-free connectors, which updated our label with recent favorable published evidence in infection control. In Q1, we received 2 additional 510(k) clearances, which were some of the images that have been highlighted in our investor deck. First, we received approval for an adjacent product in our oncology line that bonds our market-leading Clave needle-free connectors to access ports and empty non-PVC, non-DEHP IV bags. The second is a 510(k) for a revised disinfection cap, which complements our existing SwabCap portfolio and provides customers with another product to assist in infection control and accessing needle-free connectors. Both thematically aligned with our effort to add safety to each step in the infusion delivery workflow and are examples of the singles and doubles we need to consistently hit for continued long-term growth in consumables. On Infusion Systems, in Q1, we received FDA approval on the latest version of our LifeShield safety software. This version includes new enhancements for improved analytics and reporting plus features to improve the experience for our large enterprise customers and to add safety in each step in the infusion delivery workflow. However, it's going to take a little bit more time to get the clearances on the new hardware platforms as the FDA is appropriately elevating testing requirements for new infusion pump submissions. Specifically, regarding the new Medfusion and CADD hardware submissions, the FDA is seeking additional testing data, which in plain English for us means a larger sample size across a larger number of set configurations. We believe the increased testing is a result of the FDA continuing to raise the bar to ensure improved safety in the infusion pump landscape. Nothing about the additional testing relates to the core product technology around its mechanism, usability, human factors, et cetera. The testing the FDA is asking us to do is standard. It's just a larger volume that takes some time to complete. Our current strategy is to prioritize finishing the testing first on Medfusion and then on to CADD. As context over the last 2.5 years in the pump business, we have successfully received 6 510(k) clearances with a first pass clearance each time, so we have the expertise to deliver on this. All in all, a lot of right things are happening in the product development process. I'll come back after Brian with how these items align with our progress against our near-term goals and to help us create a comprehensive infusion therapy company. I'll hand the call back over to Brian."
    "2. Vital Care, Inc. (NASDAQ:VCTC) reported revenue of $100 million for the first quarter of 2026, representing a 14% organic decline and a 59% reported decline due to the deconsolidation of IV Solutions from the income statement. Gross margins decreased 1.5 percentage points sequentially and were 1.5 percentage points below our expectations due to the deconsolidation of IV Solutions. Adjusted EBITDA was $10 million and adjusted EPS was $0.05. Free cash flow was $1 million, and there was no real change in net leverage. The broader demand and utilization environment in Q1 was previewed on the last call. The sharp flu spike in late 2025 did soften January, but volumes returned to expected levels from February onwards and feels fine through today. The capital environment is status quo, and it does appear investments that customers need to get done are getting done. We believe we should see sequential stability to improvement organically here and continue to believe the right revenue assumption for the near term is flat to slightly down in the face of our decisions to improve profitability. I wanted to close the business unit commentary with some updates on the different product development initiatives within the company. As we've mentioned more recently, we've been increasing the volume of new 510(k) submissions for our consumables offerings where the innovation is more incremental and intended to create new adjacent niches. Last year, we received a new 510(k) for our core microclve and Neutron needle-free connectors, which updated our label with recent favorable published evidence in infection control. In Q1, we received 2 additional 510(k) clearances, which were some of the images that have been highlighted in our investor deck. First, we received approval for an adjacent product in our oncology line that bonds our market-leading Clave needle-free connectors to access ports and empty non-PVC, non-DEHP IV bags. The second is a 510(k) for a revised disinfection cap, which complements our existing SwabCap portfolio and provides customers with another product to assist in infection control and accessing needle-free connectors. Both thematically aligned with our effort to add safety to each step in the infusion delivery workflow and are examples of the singles and doubles we need to consistently hit for continued long-term growth in consumables. On Infusion Systems, in Q1, we received FDA approval on the latest version of our LifeShield safety software. This version includes new enhancements for improved analytics and reporting plus features to improve the experience for our large enterprise customers and to add safety in each step in the infusion delivery workflow. However, it's going to take a little bit more time to get the clearances on the new hardware platforms as the FDA is appropriately elevating testing requirements for new infusion pump submissions. Specifically, regarding the new Medfusion and CADD hardware submissions, the FDA is seeking additional testing data, which in plain English for us means a larger sample size across a larger number of set configurations. We believe the increased testing is a result of the FDA continuing to raise the bar to ensure improved safety in the infusion pump landscape. Nothing about the additional testing relates to the core product technology around its mechanism, usability, human factors, et cetera. The testing the FDA is asking us to do is standard. It's just a larger volume that takes some time to complete. Our current strategy is to prioritize finishing the testing first on Medfusion and then on to CADD. As context over the last 2.5 years in the pump business, we have successfully received 6 510(k) clearances with a first pass clearance each time, so we have the expertise to deliver on this. All in all, a lot of right things are happening in the product development process. I'll come back after Brian with how these items align with our progress against our near-term goals and to help us create a comprehensive infusion therapy company. I'll hand the call back over to Brian."
    "2. Vital Care, Inc. (NASDAQ:VCTC) reported revenue of $100 million for the first quarter of 2026, representing a 14% organic decline and a 59% reported decline due to the deconsolidation of IV Solutions from the income statement. Gross margins decreased 1.5 percentage points sequentially and were 1.5 percentage points below our expectations due to the deconsolidation of IV Solutions. Adjusted EBITDA was $10 million and adjusted EPS was $0.05. Free cash flow was $1 million, and there was no real change in net leverage. The broader demand and utilization environment in Q1 was previewed on the last

<|assistant|>
<|assistant|>
<|assistant|>

The same 14-character fragment repeats 292 times until the token limit. Showing the first three.